Clinical Study of Two Differential Esomeprazole-based One-week Triple Therapy Regimens for Duodenal Ulcer with Helicobacter pylori Infection

Objective To evaluate the efficacy,tolerability,drug compliance and adverse effects of two differential esomeprazole-based one-week triple therapy regimens for duodenal ulcer(DU) with Helicobacter pylori infection.Methods A prospective,randomized positive controlled trial study was designed.A total of 94 H.pylori-positive patients with active DU received twice daily treatment with esomeprazole 20 mg combination with amoxicillin 1 g and clarithromycin 500 mg or furazolidone 0.1 g for 1 week(EAC and EFA group,n=46 and 48,respectively).The follow-up remissive rate of clinical symptoms,ulcer healing rate(by endoscopies),H.pylori status,adverse effect,2-year ulcer recurrence of all patients were performed 4 weeks after the completion of therapy.Results 90 patients completed the trial.4 patients dropped out.According to the per-protocol(PP) analysis,the remissive rate of clinical symptoms were: upper abdominal pain relief rate(100% vs.100%,P=0.483),water brash(90.9% vs.917%,P=1.000),heartburn((93.8%) vs.95%,P=1.000) in-group EAC and EFA respectively.Ulcer healing rates for per-protocol populations were 95.5% and 93.5 %(P0.05);Corresponding H.pylori eradication rates were 90.9% and 100%(P0.05);Corresponding 2-year ulcer recurrence were 7.5% and 5.0%(P0.05).Both eradication regimens were well tolerated,and patient compliance was high.Conclusion The efficacy,tolerance,adverse effects and drug compliance of two differential esomeprazole-based one-week triple therapy regimens for duodenal ulcer with Helicobacter pylori infection is similar to each other,either of which can be used as higher eradication rate therapy regimens.